Form 4: Moderna Director Receives Equity Grant

Moderna director Elizabeth E. Tallett was granted 8,371 restricted stock units as part of annual compensation.

Summary

• Director Elizabeth E. Tallett received an award of 8,371 restricted stock units (RSUs) on May 6, 2026.
• The RSUs convert to common stock on a one-for-one basis.
• The award is subject to a vesting schedule tied to continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard director compensation practices.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• None identified; this is a standard compensatory equity grant.

Risks

• Vesting is contingent upon the recipient's continued service to the company.

Future Outlook

The RSUs will vest in full on the earlier of May 6, 2027, or the date of the next Annual Meeting of Shareholders.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are a standard corporate governance practice in the biotechnology sector to ensure board members maintain a vested interest in company performance.

Comparison to Industry Standards

• The grant structure is consistent with standard equity compensation packages for independent directors at large-cap pharmaceutical and biotech firms.

Stakeholder Impact

• Minor dilution impact to existing shareholders upon eventual vesting and conversion of RSUs.

Next Steps

• Vesting of the RSU award on May 6, 2027, or the next Annual Meeting of Shareholders.

Key Dates

Keywords

Moderna, MRNA, Form 4, Insider Trading, Equity Compensation, Director Compensation